Stock Events

Enzo Biochem 

$1.06
20
-$0.01-0.93% Friday 20:00

統計

當日最高
1.06
當日最低
1
52週最高
1.84
52週最低
0.99
成交量
148,822
平均成交量
138,494
市值
54.55M
市盈率
1.19
股息收益率
-
股息
-

收益

13Jun確認
Q3 2022
Q3 2022
Q4 2022
Q1 2023
Q3 2023
Q4 2023
Q1 2024
-0.31
-0.22
-0.13
-0.04
預期每股收益
N/A
實際每股收益
-0.04

人們還關注

此列表基於在 Stock Events 上關注 ENZ 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Health Technology
Biotechnology
Professional, Scientific, and Technical Services
Testing Laboratories
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing ‘STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.
Show more...
首席執行官
Elazar Rabbani
員工
179
國家
US
ISIN
US2941001024
WKN
000865607

上市公司